[go: up one dir, main page]

WO2006078271A3 - Cloning and expression of the full length 110 kda antigen of orientia tsutsugamushi to be used as a vaccine component against scrub typhus - Google Patents

Cloning and expression of the full length 110 kda antigen of orientia tsutsugamushi to be used as a vaccine component against scrub typhus Download PDF

Info

Publication number
WO2006078271A3
WO2006078271A3 PCT/US2005/013255 US2005013255W WO2006078271A3 WO 2006078271 A3 WO2006078271 A3 WO 2006078271A3 US 2005013255 W US2005013255 W US 2005013255W WO 2006078271 A3 WO2006078271 A3 WO 2006078271A3
Authority
WO
WIPO (PCT)
Prior art keywords
tsutsugamuchi
cloning
expression
kda
full length
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/013255
Other languages
French (fr)
Other versions
WO2006078271A2 (en
Inventor
Wei-Mei Ching
Chien-Chung Chao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Navy
Original Assignee
US Department of Navy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Navy filed Critical US Department of Navy
Publication of WO2006078271A2 publication Critical patent/WO2006078271A2/en
Anticipated expiration legal-status Critical
Publication of WO2006078271A3 publication Critical patent/WO2006078271A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The inventive subject matter relates to a recombinant 110 kDa protein from O. tsutsugamuchi, Karp, Kato and Gilliam strains and for a DNA expression system containing DNA encoding the 110 kDa protein of O. tsutsugamuchi. The invention also relates to the use of these recombinant contructs in a formulation for the induction of a protective immune response against O. tsutsugamuchi invection using. The inventive subject matter also relates to a recombinant 110 kDa O. tsutsugamuchi protein or 110 kDa fragments for the production of antigen for use in immunodiagnosistic asssays for scrub typhus.
PCT/US2005/013255 2004-04-20 2005-04-19 Cloning and expression of the full length 110 kda antigen of orientia tsutsugamushi to be used as a vaccine component against scrub typhus Ceased WO2006078271A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56347704P 2004-04-20 2004-04-20
US60/563,477 2004-04-20

Publications (2)

Publication Number Publication Date
WO2006078271A2 WO2006078271A2 (en) 2006-07-27
WO2006078271A3 true WO2006078271A3 (en) 2006-12-21

Family

ID=36692655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/013255 Ceased WO2006078271A2 (en) 2004-04-20 2005-04-19 Cloning and expression of the full length 110 kda antigen of orientia tsutsugamushi to be used as a vaccine component against scrub typhus

Country Status (1)

Country Link
WO (1) WO2006078271A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020193330A1 (en) * 2000-09-08 2002-12-19 David Hone Genetically engineered co-expression DNA vaccines, construction methods and uses thereof
US20030165523A1 (en) * 1997-12-24 2003-09-04 Wei-Mei Ching Truncated recombinant major outer membrane protein antigen (R56) of orientia tsutsugamushi strains Karp, Kato and gilliam and its use in antibody based detection assays and vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165523A1 (en) * 1997-12-24 2003-09-04 Wei-Mei Ching Truncated recombinant major outer membrane protein antigen (R56) of orientia tsutsugamushi strains Karp, Kato and gilliam and its use in antibody based detection assays and vaccines
US20020193330A1 (en) * 2000-09-08 2002-12-19 David Hone Genetically engineered co-expression DNA vaccines, construction methods and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COKER ET AL.: "Development of Rickettsia prowazekii DNA vaccine", ANN. N.Y. ACAD. SCI., vol. 990, 2003, pages 757 - 764, XP003005582 *
MIERENDORF ET AL., INNOVATIONS, vol. 1, no. 1, May 1994 (1994-05-01), pages 1 - 3 *
OAKS ET AL.: "Molecular cloning and expression of Rickettsia tsutsugamushi genes for two major protein antigens in Escherichia coli", INFECT. IMMUN., vol. 55, no. 5, May 1987 (1987-05-01), pages 1156 - 1162, XP003005902 *

Also Published As

Publication number Publication date
WO2006078271A2 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
WO2009139928A3 (en) Recombinant chimeric antigens for diagnosis and prevention of scrub typhus
WO2008020335A8 (en) Immunogenic compositions for streptococcus agalactiae
WO1999057280A3 (en) Neisseria meningitidis antigens and compositions
WO2005121331A8 (en) Truncated galnact2 polypeptides and nucleic acids
WO2005039501A3 (en) Immunogenic composition and method of developing a vaccine based on fusion protein
ATE286072T1 (en) SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES HOMOLOGUE TO AMYLOID BETA AND THEIR USE TO INDUCE AN IMMUNE RESPONSE AGAINST AMYLOID BETA AND AMYLOID AGGREGATES
WO2001096368A3 (en) Use of coiled-coil structural scaffold to generate structure-specific peptides
WO2008011609A3 (en) Compositions and methods for vaccinating against hsv-2
MY150105A (en) A novel surface exposed haemophilus influenzae protein (protein e; pe)
IL180101A (en) Isolated peptides, class-i mhc/peptide complex, nucleic acids encoding said peptides, immunogenic compositions comprising said peptides or said nucleic acids and their use in the preparation of medicaments
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
ATE407945T1 (en) ABUNDANT EXTRACELLULAR PRODUCTS AND METHODS FOR THEIR PRODUCTION AND THEIR USE
PL1618128T3 (en) Tuberculosis vaccine with improved efficacy
WO2005030793A3 (en) Antibodies which bind human cxcr3
WO2008010098A3 (en) Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
WO2018102774A8 (en) Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a
WO2008086386A8 (en) Adenoviral vector-based malaria vaccines
WO2004085466A8 (en) Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
WO2000037646A3 (en) Group b streptococcus proteins, and their use
WO2003095480A3 (en) Brachyspira hyodysenteriae vaccine
WO2007016598A3 (en) Influenza vaccine compositions and methods of use thereof
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
WO2006078271A3 (en) Cloning and expression of the full length 110 kda antigen of orientia tsutsugamushi to be used as a vaccine component against scrub typhus
WO2013171661A3 (en) Adjuvant formulations and methods
DE69840326D1 (en) INCREASING IMMUNE RESPONSE USING TARGETED MOLECULES

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase